Ainos (AIMD) Issues Mid-Year Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
June 16, 2025 8:01 AM EDTAI Nose Platform Advances Toward Scaled Pilot Programs Across Healthcare, Robotics, and Industrials
VELDONA® Oral Interferon Receives Approval to Begin Human Trials in Taiwan
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Ainos, Inc. (NASDAQ: AIMD)(NASDAQ: AIMDW) ("Ainos" or the "Company") today issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven... More
